Sector Pulse — August 29, 2026

Technology

Theme

AI infrastructure remains the market’s dominant technology narrative, but leadership is broadening from GPUs into memory, networking, optical connectivity, cybersecurity, cloud software, and enterprise deployment. The sector is increasingly split between companies converting AI demand into cash flow and those relying on aggressive valuation assumptions, debt, or future adoption.

Movers

NVDA(NVIDIA): Q2 revenue reached $96 billion, while Amazon tripled its GPU orders and NVIDIA agreed to acquire Hugging Face for $12.9 billion. NVIDIA is extending its moat from GPUs into memory, networking, storage, and AI software, reinforcing its position as the sector bellwether.
AMD(AMD): Bank of America and Raymond James upgraded the stock, highlighting its valuation, server CPU exposure, and role as a credible second source to NVIDIA. The key implication is that hyperscaler efforts to diversify AI suppliers are creating a durable share-gain opportunity.
MU(Micron): Contracted AI memory revenue and HBM demand are accelerating, while NVIDIA’s rising memory costs confirm that suppliers are capturing pricing power. The risk is a future supply response from Samsung and SK hynix.
MRVL(Marvell Technology): Revenue grew 37% and data-center revenue rose 46%, but the stock fell after guidance failed to meet elevated expectations. Strong fundamentals are no longer sufficient when hyperscaler execution is priced for perfection.
ANET(Arista Networks), COHR(Coherent), and LITE(Lumentum): Citi identified networking and optical connectivity as the next AI bottlenecks. Arista’s switching, Coherent’s photonics, and Lumentum’s transceivers are gaining strategic importance as data movement becomes as critical as compute.
ALAB(Astera Labs): AI infrastructure partnerships and strong Q2 execution support the growth narrative, but a 135.9x P/E and high customer concentration make the stock vulnerable to any hyperscaler capex slowdown.
ASML(ASML Holding) and TSM(Taiwan Semiconductor Manufacturing): Both remain foundational to advanced-chip production, but valuation and geopolitical risks are diverging. ASML trades at a substantial premium to modeled value, while TSMC offers stronger earnings support but remains exposed to Taiwan and China risks.
LRCX(Lam Research), ADI(Analog Devices), and INTC(Intel): Bank of America included all three among preferred semiconductor buys during a potential SOX pullback. The call favors “picks-and-shovels” exposure over the most crowded AI names.
SNPS(Synopsys): Revenue rose 42%, but Ansys-related amortization, stock compensation, debt, and restructuring costs created a wide gap between adjusted and GAAP profitability. Integration execution is now central to the thesis.
HPQ(HP): Revenue and guidance beat expectations, but PC units fell 16% and Personal Systems margin dropped to 4.6%. AI PCs may reach half of the mix by year-end, yet pricing inflation is masking weaker demand.
IBM(IBM) and ARM(Arm Holdings): Their 2nm dual-architecture processor for IBM Z and LinuxONE systems expands Arm’s enterprise credibility and supports IBM’s on-premises AI and data-sovereignty strategy. IBM’s quantum partnership with HRL adds another long-duration option, though a senior executive’s large share sale offsets some of the optimism.
ORCL(Oracle), MSFT(Microsoft), AMZN(Amazon), GOOG(Alphabet), and GOOGL(Alphabet): Hyperscalers are committing heavily to AI compute, custom silicon, and power infrastructure. The upside is platform control and customer lock-in; the risk is rising capex, margin compression, and increasing competition among AWS, Azure, and Google Cloud.
CRM(Salesforce), WDAY(Workday), NOW(ServiceNow), ESTC(Elastic), SNOW(Snowflake), NTNX(Nutanix), and DOCU(DocuSign): Enterprise AI adoption is becoming tangible through agents, model routing, workflow automation, and agreement intelligence. However, backlog deceleration, margin pressure, and unclear AI monetization remain important discriminators.
CRWD(CrowdStrike), PANW(Palo Alto Networks), OKTA(Okta), FTNT(Fortinet), ZS(Zscaler), and NTSK(Netskope): CrowdStrike’s AIDR and Falcon Flex growth triggered a broad cybersecurity rally. Okta’s new-product bookings and machine-identity positioning were particularly strong, but valuations across the group now require sustained AI-driven demand.
PLTR(Palantir Technologies): Palantir’s concentration of forward-deployed engineering talent gives it a differentiated deployment moat, supporting Truist’s $223 target. The company remains one of the cleaner ways to express enterprise AI execution rather than AI infrastructure spending.
MDB(MongoDB), PTC(PTC), TTAN(ServiceTitan), and U(Unity Software): These names are being judged on whether AI expands their platforms or commoditizes them. MongoDB’s upcoming results are a key test of whether AI is generating real database demand, while Unity’s tax-driven CFO sale is not a fundamental negative.
IONQ(IonQ), QBTS(D-Wave Quantum), and Q(Qnity Electronics): Quantum names remain highly speculative. IonQ has strong bookings and cloud distribution, while D-Wave combines commercial traction with 500x sales, heavy dilution, insider selling, and CFO turnover. Q’s decline lacked company-specific news and reflects weak sentiment toward non-AI technology.

Actionable Ideas (Positive)

AMD(AMD): Buy pullbacks into semiconductor weakness. Its valuation is materially more defensible than the highest-multiple AI names, while hyperscaler diversification creates a credible second-source opportunity.
ANET(Arista Networks), COHR(Coherent), and LITE(Lumentum): Favor the networking and optical layer of AI infrastructure. The bottleneck is shifting from compute availability to data movement, supporting multi-year demand.
CRWD(CrowdStrike): Maintain a bullish bias on continued AIDR and platform-module adoption. The company is converting AI-generated attack surfaces into an “AI security tax,” although position sizing should reflect premium valuation.
PLTR(Palantir Technologies): Buy on weakness as a high-conviction AI deployment play. Its forward-deployed engineering network is a harder-to-replicate moat than generic model access.
LRCX(Lam Research) and ADI(Analog Devices): Use semiconductor pullbacks to build exposure to equipment and analog components with structural AI, industrial, and memory tailwinds.

Actionable Ideas (Negative)

ALAB(Astera Labs): Avoid chasing the rally. The valuation assumes near-monopoly economics and leaves the stock acutely exposed to hyperscaler supplier changes.
MRVL(Marvell Technology): Treat as a tactical short or underweight until Google-related custom-chip execution accelerates. Strong reported growth is being discounted because expectations are even higher.
IONQ(IonQ) and QBTS(D-Wave Quantum): Avoid as core holdings. Extreme valuations, dilution, operating losses, and insider selling create poor risk-adjusted exposure despite attractive technology narratives.
ORCL(Oracle): Underweight against stronger hyperscaler balance sheets. The $83 billion financing plan raises leverage and dilution risk while cash flow is already under pressure.
SNPS(Synopsys): Avoid aggressive positioning until Ansys integration produces measurable cross-selling and GAAP profitability improves.

Financials

Theme

Financials are benefiting from resilient capital markets, wealth-management expansion, digital assets, and potential stabilization in interest-rate markets. At the same time, regulatory failures, credit sensitivity, and the cost of funding innovation are separating durable franchises from narrative-driven turnarounds.

Movers

JPM(JPMorgan Chase): Delivered $57 billion in revenue and 23% ROTCE, but its Indian unit was banned by SEBI over alleged market manipulation. The regulatory event is more consequential than the earnings beat because it tests global compliance controls.
BAC(Bank of America), CM(CIBC), TD(Toronto-Dominion Bank), MUFG(Mitsubishi UFJ Financial Group), and WFC(Wells Fargo): Strong earnings, improved credit quality, yen intervention, and wealth-management hiring supported broad financial-sector strength. WFC’s advisor recruitment is a tangible test of its post-scandal business rebuild.
DB(Deutsche Bank): Announced a €500 million buyback and partnered with Google Cloud on regulated financial-services AI. The combination offers capital-return support and a potential efficiency catalyst, but core earnings momentum remains less proven.
IBKR(Interactive Brokers) and RJF(Raymond James Financial): Both have delivered exceptional long-term returns and high profitability, but valuations assume sustained trading activity. Their upside depends on continued client growth and market participation.
AFRM(Affirm), KLAR(Klarna), PYPL(PayPal), and SHOP(Shopify): BNPL is bifurcating sharply. Klarna and Affirm are expanding internationally and through embedded checkout, while PayPal’s failed $53 billion acquisition bid exposed stagnation and strategic drift.
BLK(BlackRock), SCHW(Charles Schwab), COIN(Coinbase), and FNMA(Fannie Mae): Institutional crypto adoption is moving into mainstream distribution, brokerage, ETFs, and mortgage collateral. This creates a new fee pool but also introduces volatility, regulatory, and underwriting risks.
NTRS(Northern Trust): Project Acacia and its Commonwealth Superannuation partnership advance a tokenized-asset servicing strategy. Execution will determine whether digital assets offset traditional custody fee pressure.
FITB(Fifth Third Bancorp) and TFC(Truist Financial): Both paused distribution of Delaware Life-related products amid federal scrutiny of affiliated loans. The episode creates reputational and regulatory risk for their wealth and advisory platforms.
MSCI(MSCI): Turkey’s transparency and free-float issues could threaten its emerging-market classification. A downgrade would pressure Turkish inflows and reinforce MSCI’s role as a gatekeeper of market access.

Actionable Ideas (Positive)

TD(Toronto-Dominion Bank): Favor the stock within large-cap banking. Broad Canadian and U.S. growth, falling provisions, and disciplined risk management provide the cleanest earnings signal in the group.
AFRM(Affirm): Buy selectively on evidence that Australia maintains strong GMV and credit quality. The Affirm Card and Shopify distribution can expand transaction frequency and improve operating leverage.
SCHW(Charles Schwab): Positive on the crypto-platform expansion as a customer-acquisition and fee-growth catalyst. Schwab combines a strong balance sheet with a large retail distribution network.
DB(Deutsche Bank): Buy only as an execution-oriented turnaround. The buyback provides support, while regulated AI tools could improve cost efficiency and client monetization.

Actionable Ideas (Negative)

PYPL(PayPal): Maintain a bearish stance. The failed acquisition bid removes an external escape route while transaction-margin dollars, earnings, and net income are stagnating.
JPM(JPMorgan Chase): Underweight the international-regulatory risk. The SEBI ban could lead to broader scrutiny of controls and emerging-market operations.
IBKR(Interactive Brokers): Avoid adding at current multiples. A 38.5x P/E leaves the stock exposed to a sharp earnings reset if market volumes or rates weaken.
FITB(Fifth Third Bancorp) and TFC(Truist Financial): Avoid until Delaware Life-related regulatory uncertainty clears. The risk is not only legal expense but damage to high-margin advisory distribution.

Healthcare

Theme

Healthcare leadership is shifting toward high-value obesity, oncology, rare-disease, and platform-driven innovation. Large-cap pharma offers cash flow and scale, but patent cliffs, reimbursement pressure, trial failures, and distributor concentration are becoming more immediate valuation drivers.

Movers

LLY(Eli Lilly): Mounjaro and Zepbound continue to create a high-retention growth engine, while Retatrutide and direct-to-consumer distribution provide additional optionality. Lilly is widening the gap with slower-growth diversified pharma.
JNJ(Johnson & Johnson): The Sail Biomedicines deal and in-vivo CAR-T option expand its pipeline into potentially transformative autoimmune and oncology applications. Strong cash flow and diversification support the premium multiple.
ABBV(AbbVie): Skyrizi and Rinvoq support current cash generation, but biosimilar exposure, leverage, and dependence on a narrow product base make the Apogee acquisition look defensive rather than transformative.
BMY(Bristol-Myers Squibb): The stock remains inexpensive with a strong pipeline, but the 2028 Eliquis patent expiration is the central replacement-product test.
REGN(Regeneron): FDA approval of Pasatru for FOP validates Regeneron’s rare-disease platform and broadens the pipeline beyond EYLEA. Commercial uptake and payer acceptance now matter more than regulatory validation.
RVMD(Revolution Medicines): FDA approval of Rasonque creates a major pancreatic-cancer opportunity, but the stock had already rallied sharply and now faces reimbursement, competition, and first-line efficacy tests.
MRNA(Moderna): Positive oncology data supported a $2 billion convertible financing, but shrinking revenue, cash burn, dilution risk, and extreme volatility remain central.
SAN(Sanofi): Permanent termination of its pediatric RSV vaccine trial is a major R&D and governance setback, with regulatory scrutiny potentially affecting the broader vaccine pipeline.
HIMS(Hims & Hers Health): Revenue grew 38% and EBITDA guidance rose, but FTC litigation, privacy claims, billing disputes, and Visa monitoring threaten the trust-based subscription model.
VTRS(Viatris): Complex generics and cost discipline support a turnaround thesis, but pricing erosion and regulatory execution remain decisive.
MCK(McKesson), COR(Cencora), and CAH(Cardinal Health): Pharmaceutical distributors are becoming strategically central as biopharma companies depend heavily on a small distribution network. McKesson’s Precision Medicine acquisition adds growth, but concentration risk is systemic across the sector.
BSX(Boston Scientific) and TFX(Teleflex): Insider buying at Boston Scientific supports a recovery thesis, while Teleflex’s BIOTRONIK integration must deliver the synergies needed to justify conflicting valuation signals.
GSK(GSK): The company is increasingly positioned as a challenger in metabolic disease, though pipeline progress—not analyst endorsements—will determine whether it can pressure Lilly.

Actionable Ideas (Positive)

LLY(Eli Lilly): Maintain a core bullish position. The obesity franchise has superior visibility, retention, and scale, while Retatrutide offers another potential step-up in market share.
REGN(Regeneron): Buy on weakness as a platform-driven biotech compounder. Pasatru validates the rare-disease engine and reduces reliance on a single legacy product.
MCK(McKesson): Favor the distributor transformation if integration remains disciplined. Precision Medicine adds higher-value services to a structurally essential distribution network.
BMY(Bristol-Myers Squibb): Suitable for value and income investors willing to underwrite the Eliquis cliff. The valuation offers upside if pipeline launches offset the 2028 loss.

Actionable Ideas (Negative)

ABBV(AbbVie): Underweight into the biosimilar and IRA-pricing cycle. Product concentration and leverage leave limited room for pipeline delays.
HIMS(Hims & Hers Health): Avoid despite strong growth until litigation and dispute rates stabilize. Regulatory action could impair customer acquisition economics and recurring revenue.
SAN(Sanofi): Maintain a negative bias after the RSV trial failure. The event damages confidence in pediatric vaccine oversight and could delay future programs.
MRNA(Moderna): Avoid as a core holding. The convertible financing extends the runway but does not solve commercial losses or the risk of future dilution.

Industrials

Theme

Industrials are increasingly being re-rated as AI infrastructure suppliers rather than traditional cyclicals. Defense backlogs, grid equipment, aviation, automation, and distributed power are attracting capital, but valuations now demand flawless execution and stable government or hyperscaler spending.

Movers

CAT(Caterpillar): Power-generation revenue is approaching construction revenue and is more profitable, supported by a $72 billion backlog. AI data-center power demand is turning Caterpillar into an infrastructure growth story, but the stock now trades at a premium industrial multiple.
ETN(Eaton) and TT(Trane Technologies): Their partnership integrates electrical and thermal systems for NVIDIA-aligned data centers. This is a direct route into the AI power bottleneck, with concentration risk if data-center construction slows.
GEV(GE Vernova) and GE(General Electric): GE Vernova’s HVDC joint venture in Korea and the appointment of Claire McDonough as CFO reinforce its grid-modernization strategy. The large backlog has yet to translate into equivalent EBITDA growth.
BWXT(BWX Technologies): The U.S. Army selected BWXT’s advanced reactor for the $2.2 billion Janus program. The award could establish a leadership position in military microreactors, but the 2028 deployment schedule is demanding.
GD(General Dynamics): A $136.5 billion backlog and strong Q2 execution provide exceptional earnings visibility. Aerospace and Marine Systems remain the key execution dependencies.
BA(Boeing): The potential strike by 17,000 engineers threatens FAA certification and production milestones for the 737 MAX 10 and 777-9. The defense pipeline is attractive, but labor and execution risk dominate the near-term setup.
AVAV(AeroVironment): The AV Eagle joint venture in Greece expands European defense exposure, while the NASA Mars helicopter role validates autonomy capabilities. Contract conversion and legal overhangs remain the key tests.
HWM(Howmet Aerospace): Engine-component capacity expansion supports long-term growth, but a 56.5x P/E leaves no margin for slower aircraft build rates or customer renegotiations.
CARR(Carrier Global), GWW(W.W. Grainger), TER(Teradyne), and VMC(Vulcan Materials): Each faces a valuation-versus-execution tension. Data-center cooling and automation provide structural upside, while legal, cyclical, and demand risks are not fully reflected in prices.
PCAR(PACCAR): Earnings beat expectations and parts revenue remain resilient, but truck-cycle and tariff risks explain the recent pullback. Electrification execution will determine whether the valuation discount closes.
RIVN(Rivian): CFO Claire McDonough’s departure to GE Vernova is a significant talent-retention negative as Rivian enters its most capital-intensive period.

Actionable Ideas (Positive)

GD(General Dynamics): Buy on weakness for backlog visibility and defense-budget durability. The order book provides a superior earnings floor to most industrial peers.
ETN(Eaton) and TT(Trane Technologies): Accumulate selectively as AI power infrastructure beneficiaries. Their joint electrical-thermal offering addresses a real deployment bottleneck rather than a purely narrative market.
BWXT(BWX Technologies): Favor for long-term advanced-nuclear exposure, with the Janus award serving as a powerful validation event. Position size should reflect prototype and schedule risk.
PCAR(PACCAR): Buy weakness if commercial-vehicle demand stabilizes. Parts and service cash generation provide resilience while the company invests in connected and lower-emission trucks.

Actionable Ideas (Negative)

BA(Boeing): Maintain a bearish bias until the SPEEA dispute is resolved. A strike during certification work could compound delivery, regulatory, and credibility problems.
HWM(Howmet Aerospace) and VMC(Vulcan Materials): Avoid chasing strong performance at current valuation levels. Both stocks require aggressive growth assumptions to justify their multiples.
RIVN(Rivian): Stay underweight. The CFO departure during the R2 ramp raises financing and execution risk at precisely the wrong point in the cycle.

Transportation

Theme

Transportation news favors operators with pricing power, asset-light economics, or visible infrastructure investment. Aviation and cruising show strong demand, but leverage, fleet timing, and exposure to travel disruptions remain the dominant risks.

Movers

UAL(United Airlines): The A321XLR rollout will open underserved European routes with lower-cost long-haul capacity. On-time delivery and sustained fare strength are the key catalysts.
VIK(Viking Holdings): Advance bookings cover 96% of 2026 capacity and 53% of 2027, supporting exceptional visibility. Debt and European river disruptions remain the main constraints.
UPS(United Parcel Service): A $2 billion infrastructure program targets healthcare logistics and international hubs. The investment supports long-term network competitiveness, although near-term margins remain capital-intensive.
UBER(Uber): The Lucid-Nuro alliance offers a pragmatic path into autonomous mobility without owning the vehicle fleet. Regulatory exposure, including an €825 million Dutch fine, remains the principal offset.
H(Hyatt Hotels): The asset-light model and 138,000-room development pipeline support growth, but premium valuation and luxury-market sensitivity leave limited room for execution misses.
MAR(Marriott International) and HST(Host Hotels & Resorts): Marriott’s cautious profit guidance pressured hotel REITs, highlighting the operating dependence of property owners on brand partners.

Actionable Ideas (Positive)

UAL(United Airlines): Favor as the strongest airline growth setup. A321XLR deployment can expand transatlantic routes with better economics than widebody capacity.
UPS(United Parcel Service): Buy selectively for defensive logistics exposure and healthcare-network expansion. The valuation is more reasonable than many AI-linked growth alternatives.
VIK(Viking Holdings): Positive on demand visibility, but only for investors comfortable with leverage and itinerary disruption risk.

Actionable Ideas (Negative)

HST(Host Hotels & Resorts): Underweight as long as Marriott guidance and rates remain problematic. Partner concentration and financing sensitivity create a poor near-term risk profile.
H(Hyatt Hotels): Avoid chasing the rally. The development pipeline is attractive, but a premium P/S multiple and discretionary exposure leave the stock vulnerable to softer travel demand.

Consumer Discretionary

Theme

Consumers are trading down, but demand remains polarized. Beauty, value retail, international franchising, and digital marketplaces are holding up, while footwear, legacy brands, home improvement, and premium discretionary categories face volume and margin pressure.

Movers

DKS(DICK’S Sporting Goods): The Foot Locker acquisition triggered a 27% selloff after comparable sales fell and guidance reversed to decline. The episode challenges the strategic logic of the deal and exposes the cost of inheriting a weak athletic-footwear chain.
NKE(Nike): Converse posted its 13th consecutive quarterly revenue decline, prompting new operating and commercial leadership. The turnaround now looks like portfolio triage rather than a normal brand refresh.
ULTA(Ulta Beauty): Sales rose 8.9% and operating income increased 10.1%, but Space NK diluted gross margin while debt-funded buybacks raise capital-allocation risk.
EBAY(eBay): Revenue growth accelerated to 14.4%, supported by AI tools, advertising, and marketplace efficiency. The executive share sale was a tax settlement, not a confidence signal.
DPZ(Domino’s Pizza): China franchisee DPC Dash delivered 20.8% revenue growth and 33.7% transaction growth. China has become a material validation of Domino’s international scaling model.
HD(Home Depot) and LOW(Lowe’s): Home improvement demand is concentrated in smaller repairs rather than large projects. Home Depot retains the competitive edge, while Lowe’s continues to lag despite some operational resilience.
TGT(Target), WMT(Walmart), and BBY(Best Buy): Value positioning remains important, but slowing traffic, declining unit volumes, and tariff-refund distortions show that consumer resilience is increasingly price-driven rather than volume-driven.
TJX(TJX Companies), ROST(Ross Stores), BURL(Burlington Stores), DG(Dollar General), and DLTR(Dollar Tree): Off-price and discount formats are attracting higher-income consumers. However, price increases, inventory risk, and dependence on tariff refunds could undermine the value proposition.
TTWO(Take-Two Interactive): The stock is priced heavily around GTA VI. Any delay or weak launch would expose a major single-product valuation risk.
EA(Electronic Arts): The €250 million Bundesliga licensing deal strengthens EA Sports FC’s content moat, but weak Apex Legends bookings limit portfolio diversification.
MELI(MercadoLibre): Its integrated e-commerce, payments, logistics, and credit platform remains the benchmark for Latin American digital growth.

Actionable Ideas (Positive)

MELI(MercadoLibre): Maintain a bullish stance on the regional ecosystem leader. Payments, logistics, and credit reinforce each other and provide stronger economics than a standalone marketplace.
DPZ(Domino’s Pizza): Buy on weakness if China growth remains intact. DPC Dash is demonstrating that international royalties can become a meaningful long-duration growth engine.
ULTA(Ulta Beauty): Positive on the core business, but favor exposure only after debt and Space NK profitability improve. Beauty demand is proving more resilient than broader discretionary spending.
EBAY(eBay): Buy selectively as a turnaround. AI-powered tools and advertising monetization are producing tangible revenue acceleration without the balance-sheet risk seen in newer platforms.

Actionable Ideas (Negative)

DKS(DICK’S Sporting Goods): Avoid until Foot Locker stabilizes. The acquisition has already forced lower sales, earnings, and operating-income expectations.
NKE(Nike): Maintain a negative bias. Converse’s prolonged collapse and weakening brand relevance indicate a broader portfolio-management problem.
TTWO(Take-Two Interactive): Avoid ahead of GTA VI unless risk is tightly managed. The valuation offers little protection against delay or underwhelming engagement.
BBY(Best Buy), **